Decipher Lethal Prostate Cancer Biology - Urine Metabolomics
Decipher the Biology of Lethal Prostate Cancer - Urine Metabolomics Profiling in Men Receiving Prostate Biopsy and Men With Diagnosed Prostate Cancer Receiving MCS Supplementation
Sponsor: Cardinal Tien Hospital
This NA trial investigates Significant Prostate Cancer and is currently actively recruiting participants. Cardinal Tien Hospital leads this study, which shows 13 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Feb 2026 — Present [monthly]
Recruiting NA
-
Jan 2025 — Feb 2026 [monthly]
Recruiting NA
-
Sep 2024 — Jan 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Jan 2023 — Jul 2024 [monthly]
Recruiting NA
▶ Show 8 earlier versions
-
Apr 2022 — Jan 2023 [monthly]
Recruiting NA
-
Feb 2022 — Apr 2022 [monthly]
Recruiting NA
-
Oct 2021 — Feb 2022 [monthly]
Recruiting NA
Status: Unknown Status → Recruiting · Phase: EARLY_PHASE1 → NA
-
Jan 2021 — Oct 2021 [monthly]
Unknown Status EARLY_PHASE1
-
Jun 2020 — Jan 2021 [monthly]
Unknown Status EARLY_PHASE1
Status: Recruiting → Unknown Status
-
Jun 2018 — Jun 2020 [monthly]
Recruiting EARLY_PHASE1
-
Feb 2018 — Jun 2018 [monthly]
Recruiting EARLY_PHASE1
-
Aug 2017 — Feb 2018 [monthly]
Recruiting EARLY_PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Cardinal Tien Hospital
- Chang Gung Memorial Hospital
- Far Eastern Memorial Hospital
- National Taiwan University Hospital
- Shin Kong Wu Ho-Su Memorial Hospital
- Taichung Tzu Chi Hospital
- Taipei Medical University Hospital
- Taipei Medical University Shuang Ho Hospital
- Taipei Veterans General Hospital, Taiwan
For direct contact, visit the study record on ClinicalTrials.gov .